22.08.2018
Medios AG DE000A1MMCC8
DGAP-News: Medios AG: Preliminary 1st half-year figures underpin forecast for full-year 2018
DGAP-News: Medios AG / Key word(s): Preliminary Results/Half Year Results
Medios AG: Preliminary 1st half-year figures underpin forecast for full-year
2018
22.08.2018 / 10:06
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Medios AG: Preliminary 1st half-year figures underpin forecast for full-year
2018
* Sales and key earnings figures substantially higher
* Forecast for 2018 confirmed
* Integration of essential operating units of BerlinApotheke largely
concluded as planned
Berlin, August 22, 2018 - Medios AG ("Medios") one of the leading Specialty
Pharma companies in Germany, continued its growth course in the first half
of 2018 and confirms its forecast for fiscal year 2018. According to
preliminary calculations, Group sales rose by 24% to EUR 145 million in the
first six months of the financial year (IFRS; previous year: EUR 117.0
million). Group earnings before taxes (EBT) increased by 21.5% to 4.7
million euros (IFRS; previous year: EUR 3.9 million), without taking account
of the stock option program (SOP) adopted by resolution in 2017 and before
non-recurring expenses associated with the commissioning of the laboratories
acquired in September 2017. After non-recurring expenses, amounting to
approx. 0.6 million euros, EBT excluding the SOP improved by 5.1%, to 4.1
million euros.
Manfred Schneider, CEO of Medios AG: "The high level of demand for
individualized medicine continues unabated and is a key driver of our
dynamic growth trend. Following the integration of the essential operating
units of BerlinApotheke into Medios Individual, we have further expanded our
specialty pharma spectrum and also achieved an improvement in
profitability".
The integration of essential operating units of BerlinApotheke Schneider &
Oelski oHG into the Medios Group has largely been concluded since June 1,
2018. As expected, the profitability of the company Medios Individual GmbH
will improve appreciably as a result of this strategic measure.
Matthias Gärtner, CFO of Medios AG: "All Medios Group companies reflect a
highly encouraging development. In June alone, consolidated sales exceeded
28 million euros and earnings before taxes came to approx. 1 million euros,
without taking account of the non-recurring and non-cash effects of the
stock option program. Accordingly, we are clearly on track to reach our
targets for the full-year 2018 and to establish Medios as the leading
Specialty Pharma company in Germany."
Against the backdrop of the positive development in the first half of 2018
and the planned further extension of operations, the Management of Medios AG
confirms its forecast presented in March 2018. Consolidated sales in fiscal
year 2018 are to improve to around 320 million euros and EBT (excluding the
SOP) to approx. 11 million euros. This corresponds to growth rates of 26
percent and 37 percent, compared with business figures for 2017, reaching
253 million euros and 8.0 million euros, respectively.
About Medios AG
Medios AG is one of the leading Specialty Pharma companies in Germany. As
wholesaler for Specialty Pharma drugs and GMP-certified manufacturer of
patient-specific medications, Medios covers substantial elements of the
supply chain in this field and follows the highest international quality
standards. Specialty Pharma drugs are, in particular, individualised
infusions for patients with rare or chronic diseases like cancer, HIV and
hepatitis. It is Medios' aim to provide integrated solutions along the value
chain to partners and clients, thereby ensuring an optimal pharmaceutical
care for patients.
Medios AG is Germany's first listed Specialty Pharma company. The share
(WKN: A1MMCC, ISIN: DE000A1MMCC8) is listed in the Regulated Market of the
Frankfurt Stock Exchange (General Standard) and Hamburg-Hannover Stock
Exchange.
Contact
Kirchhoff Consult AG
Anja Ben Lekhal
Borselstrasse 20
22765 Hamburg
Telephone: +49 40 60918655
Fax: +49 40 60918660
Email: [email protected]
www.kirchhoff.de
Disclaimer
This notification contains forward-looking statements that are subject to
certain risks and uncertainties. Future results may significantly deviate
from currently expected results, specifically due to various risk factors
and uncertainties such as changes in business, economic, and competitive
circumstances, exchange rate fluctuations, uncertainties about legal
disputes or investigations, and the availability of financial resources.
Medios AG assumes no responsibility whatsoever for updating the
forward-looking statements contained in this notification.
---------------------------------------------------------------------------
22.08.2018 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Medios AG
Friedrichstraße 113a
10117 Berlin
Germany
Phone: +49 30 232 566 - 800
Fax: +49 30 232 566 - 801
E-mail: [email protected]
Internet: www.medios.ag
ISIN: DE000A1MMCC8
WKN: A1MMCC
Listed: Regulated Market in Frankfurt (General Standard), Hamburg;
Regulated Unofficial Market in Dusseldorf
End of News DGAP News Service
---------------------------------------------------------------------------
716319 22.08.2018
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
Medios AG ISIN: DE000A1MMCC8 können Sie bei EQS abrufen
Gesundheit , A1MMCC , ILM1 , XETR:ILM1